Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses

Tandem Diabetes Care, Inc (NASDAQ:TNDM), a leading insulin delivery
and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal mobile device in the first month following its commercial release.

“The rapid adoption of our mobile bolus feature demonstrates the importance of our offering new technologies that provide lifestyle benefits, in addition to improved clinical outcomes, to people living with diabetes,” said John Sheridan, President and CEO of Tandem Diabetes Care. “We are committed to leading in diabetes technology by continually enhancing the solutions we provide and offering best-in-class customer care.”

The t:connect mobile app is designed to offer t:slim X2 insulin pump users the ability to program and cancel bolus insulin requests through the convenience of their compatible smartphone. It is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems and is now available on approximately 30 different devices.

“The ability to bolus from my phone has been a game changer,” said Lauren Salko, professional freestyle skier and ambassador for Tandem Diabetes Care. “The feature allows me to be more discreet and wear my pump in places I haven’t been able to before. With the freedom to bolus more easily, I feel more on top of my diabetes management.”

Current t:slim X2 pump users in the United States can add this feature at no additional cost from the comfort of their own home without having to purchase a new device. Bolus delivery from the t:connect mobile app requires a compatible smartphone model and operating system, an app update, a remote software update on the customer’s t:slim X2 insulin pump and additional training.

For more information on the process or to get started, visit

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version